Analytical Data
-
Gene name
ATRN
- Application
-
Alternative Names
DPPT-L; MGCA; Mahogany homolog
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75882
-
Expression Region
Ala84~Tyr245
-
Molecular Weight
21kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of ATRN (Ataxin-1-Related Neurodegenerative Protein) recombinant proteins emerges from the growing understanding of neurodegenerative disorders, particularly those associated with the ataxin-1 gene, which is implicated in spinocerebellar ataxia type 1 (SCA1). SCA1 is characterized by progressive degeneration of the cerebellum and other brain regions, leading to motor coordination difficulties and cognitive decline. Research has indicated that the misfolding and aggregation of ataxin-1 protein play a critical role in the pathogenesis of this condition. Consequently, generating recombinant ATRN proteins allows scientists to investigate their structural properties, interactions, and functional implications in cellular environments. This approach holds promise for elucidating the molecular mechanisms underpinning SCA1 and related neurodegenerative diseases, paving the way for potential therapeutic targets. Moreover, the ability to produce and manipulate these proteins in vitro provides crucial insights into the effects of post-translational modifications and the influence of genetic variants on protein function. Thus, the recombinant study of ATRN is vital for advancing our understanding of ataxin-1-related pathologies and developing effective interventions against neurodegeneration.
